288 related articles for article (PubMed ID: 33246490)
1. Immunological classification of gliomas based on immunogenomic profiling.
Feng Q; Li L; Li M; Wang X
J Neuroinflammation; 2020 Nov; 17(1):360. PubMed ID: 33246490
[TBL] [Abstract][Full Text] [Related]
2. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
3. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
5. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
Front Immunol; 2019; 10():1756. PubMed ID: 31428092
[No Abstract] [Full Text] [Related]
6. Multiomics Profiling and Clustering of Low-Grade Gliomas Based on the Integrated Stress Status.
Ren X; Chen X; Zhu C; Wu A
Biomed Res Int; 2021; 2021():5554436. PubMed ID: 34368351
[TBL] [Abstract][Full Text] [Related]
7. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
9. Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.
Lin P; Peng YT; Gao RZ; Wei Y; Li XJ; Huang SN; Fang YY; Wei ZX; Huang ZG; Yang H; Chen G
J Cancer Res Clin Oncol; 2020 May; 146(5):1253-1262. PubMed ID: 32065261
[TBL] [Abstract][Full Text] [Related]
10. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
Tian R; Li Y; Shu M
Front Immunol; 2021; 12():797450. PubMed ID: 35069579
[TBL] [Abstract][Full Text] [Related]
11. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
12. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
13. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
[TBL] [Abstract][Full Text] [Related]
15. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
16. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
[TBL] [Abstract][Full Text] [Related]
17. Constitutive type-1 interferons signaling activity in malignant gliomas.
Li C; Long L; Wang Y; Chi X; Zhang P; Zhang Y; Ji N
J Neurooncol; 2024 Jul; 168(3):381-391. PubMed ID: 38789844
[TBL] [Abstract][Full Text] [Related]
18. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
19. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
[TBL] [Abstract][Full Text] [Related]
20. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
